Monoclonal Antibody Drugs Booming; United Biopharmaceuticals Gains Formosa Plastics Support

Monoclonal antibody drugs are known as "magic bullets" in the pharmaceutical industry because they are highly effective and have fewer side effects due to their specificity. The biopharmaceutical company United Bio-Pharmaceuticals Corporation (UBPC), which was spun off by United Asia Biotech, is actively developing monoclonal antibody drugs; the company has received support from the Formosa Plastics Group (FPG), with Formosa Plastics Biomedical Corporation (FPMC) as a major shareholder, and Chang Gung Medical System (CGMS), which will cooperate with UBPC. The company is also supported by the Formosa Plastics Group, of which Formosa Biomedical is a major shareholder, and the Chang Gung Medical System will also collaborate with the company. Lianshang Pharmaceuticals has developed a number of monoclonal antibody drugs, including AIDS, herpes simplex virus, and anti-vascular endothelial growth factor (VEGF), with the AIDS drug being developed by the company's R&D team. Clinical trials have shown that a single drug can effectively reduce the amount of virus in the blood of an AIDS patient by 2.5-3 log10 (or about 1/1,000th of the original amount). The herpes simplex virus drug is expected to apply for new drug clinical trials by the end of this year, while the anti-vascular endothelial growth factor drug is expected to apply for new drug clinical trials between 2015 and 2016. In addition, UBS has also selected four major monoclonal antibody drugs whose patents are about to expire for biosimilarity drug development, including breast cancer treatment monoclonal antibody UB-921, rheumatoid arthritis treatment monoclonal antibody UB-721, colorectal cancer treatment monoclonal antibody UB-922, and lymphoma treatment monoclonal antibody UB-923, and is expected to apply for human clinical trials on pharmacokinetics and pharmacodynamics in 2015. The company is expected to apply for human clinical trials for pharmacokinetics and pharmacodynamics in 2015. Combining the resources of its parent company, Lianxicom and UBI Group, Lianxicom has also secured a $1.2 billion investment from Formosa Plastics Group to build a commercial mass-production protein pharmaceutical plant, and will collaborate with Chang Gung Healthcare System in research and development as well as in the clinical field, in order to benefit more patients. Subscribe to the Healthy Love LOHAS audio-visual channel, read health knowledge easier Join, every day attention to your health! LINE@ ID: @ : /supply/article/17103/ Monoclonal Antibody Drugs Booming Lianshang Pharmaceuticals Supported by Formosa Plastics Keywords: monoclonal antibody, magic bullet, Lianshang Biotechnology, Lianshang Pharmaceuticals, Formosa Plastics, Changgeng